In chronic phase chronic myeloid leukemia (CML) patients the lack of a major cytogenetic response (MCyR, <36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure we performed gene expression array profiling of CD34+ cells from two independent cohorts of imatinib-naïve chronic phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response (CCyR) or >65% Ph-positive metaphases within 12 months of imatinib therapy. Based on ANOVA p<0.1 and fold difference >I1.5I we identified 885 probe sets with differential expression between responders and non-responders, from which we extracted a 75-probe set minimal signature (classifier) that separated the two groups. Upon application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and 83% of non-responders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes with CML progression signatures and implicated β-catenin in their regulation, suggesting that chronic phase CML patients destined to fail imatinib have more advanced disease than evident by morphological criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit, while sparing good-risk patients from unnecessary toxicity.
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Abstract
In chronic phase chronic myeloid leukemia (CML) patients the lack of a major cytogenetic response (MCyR, <36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure we performed gene expression array profiling of CD34+ cells from two independent cohorts of imatinib-naïve chronic phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response (CCyR) or >65% Ph-positive metaphases within 12 months of imatinib therapy. Based on ANOVA p<0.1 and fold difference >I1.5I we identified 885 probe sets with differential expression between responders and non-responders, from which we extracted a 75-probe set minimal signature (classifier) that separated the two groups. Upon application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and 83% of non-responders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes with CML progression signatures and implicated β-catenin in their regulation, suggesting that chronic phase CML patients destined to fail imatinib have more advanced disease than evident by morphological criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit, while sparing good-risk patients from unnecessary toxicity.
Introduction
Imatinib is an effective therapy for the majority of patients with chronic phase chronic myeloid leukemia (CML). However, some 20-30% of patients fail imatinib and require alternative treatments 1;2 . The cytogenetic response at 12 months is a powerful prognosticator of outcome. In a large trial of patients treated with standard dose imatinib (400 mg daily), the projected rates of event-free survival were 97% and 93%, respectively, for patients who had attained a complete cytogenetic response [CCyR, 0%
Philadelphia chromosome positive (Ph+) metaphases] or major cytogenetic response (MCyR, <36% Ph+ metaphases), but only 81% in patients with less than MCyR at 12 months 1 . In view of the high risk of progression, an expert panel convened by the European Leukemia Net has concluded that lack of MCyR at 12 months (herein referred to as primary cytogenetic resistance) defines imatinib failure, and warrants a change in the therapeutic strategy 3 .
More intensive therapy upfront has been proposed to improve the rates of MCyR 4 . Since most patients will do well on standard therapy, it would be desirable to direct early treatment intensification to high risk patients. The best clinical predictor of primary cytogenetic resistance is the Sokal risk score 5 . In the IRIS study, the projected rate of CCyR at 48 months was only 69% of patients with a high Sokal risk compared to 91% with low risk and 84% with intermediate risk 6 . However, for clinical decisions a more reliable prognosticator is needed. Based on the promising results of gene expression profiling for response prediction in various hematologic malignancies 7-11 we had previously attempted to predict MCyR by microarray analysis of unselected blood or bone marrow white cells collected prior to therapy, but found no significant differences For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From between responders and non-responders 12 . This led us to hypothesize that detecting a signature associated with primary cytogenetic resistance might require analyzing a more primitive cell compartment. We therefore performed gene expression profiling on CD34+ cells collected prior to imatinib therapy from two independent groups of chronic phase CML patients, an initial training set of late chronic phase patients and a prospectively accrued validation set of newly diagnosed chronic phase patients. Here we report the identification of a gene classifier of CD34+ CML cells that predicts MCyR with high accuracy.
Patients and Methods
Patients. The training set was retrospectively selected from CML patients treated at Oregon Health and Science University (OHSU) between 1998 and 2004. Most of the patients had failed prior interferon-α-based therapy and were treated on phase 2 studies of imatinib prior to its regulatory approval. Eligibility criteria were a diagnosis of CML in chronic phase (based on the criteria of the IRIS trial), availability of bone marrow (BM) mononuclear cells (MNC) stored immediately prior to initiating imatinib therapy and availability of at least one year of follow-up, including karyotyping. Responders were defined as those patients with at least a partial cytogenetic response within 12 months of therapy and non-responders as all other patients. Since this response definition is inherently imprecise due to the routine sampling of only 20 metaphases and may therefore misclassify responses, the training set focused on patients with CCyR during their first year of imatinib therapy as opposed to patients who had not achieved even a minor cytogenetic response (i.e. remained at least 66% Ph+) during that time, thereby For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From reducing noise by enriching the training set for the extremes of the response spectrum.
Of 51 samples initially processed, 36 were included in the final analysis, while the remainder was excluded, since they failed to meet the minimum quality requirements for microarray analysis (see below). The second group of patients (validation set) consisted of 42 consecutive newly diagnosed chronic phase patients treated with imatinib at the University of Newcastle (United Kingdom) or Leipzig (Germany). In 23 of these patients the microarray analysis was successful. The majority of these patients were followed with metaphase karyotyping; however response was assessed by fluorescence in situ hybridization in 7/17 responders and 2/6 non-responders. In these patients CD34+ cells were selected from peripheral blood collected at diagnosis. The study was approved by the institutional review board of all participating institutions, and all subjects provided written informed consent in accordance with the Declaration of Helsinki.
Isolation of CD34+ cells. In the case of the training set MNC were purified from BM by density gradient centrifugation and cryopreserved in liquid nitrogen. Immediately prior to CD34+ cell selection, the cells were thawed at 37°C and washed in Dulbecco's phosphate buffered saline (PBS) containing 0.1% human albumin (Baxter Healthcare Corporation, Glendale, CA), 1% recombinant DNase (Pulmozyme®, Genentech, San Microarray data analysis. Low-level analysis of the Affymetrix data was conducted using the Robust Multi-array Average (RMA) algorithm 13 . Only Perfect Match intensities were used. Parameters for RMA included model-based background correction, quantile normalization and median polish. Transcript-by-transcript (i.e., unique Affymetrix Probe set IDs) ANOVA to determine differential expression between NR and R was performed on the training set (N=36). All p-values were False Discovery Rate (FDR) adjusted. With respect to feature selection was based on effect size (fold change (FC) >|1.5|) and statistical significance (p-value < 0.1) to minimize false negatives. Data was further filtered based on threshold expression level and variability (based on CV). Class prediction was performed using the nearest shrunken centroids algorithm 14 . Testing of the classifier was performed on an independent, blinded validation set (N=23). The raw (cel) and normalized data were deposited in NCBI GO database (GSE14671).
Structural analysis of the classifier.
With regard to downstream analysis of the classifier, over-represented gene ontology and pathway annotations were identified in the classifier transcripts using categorical data analysis (with adjustment for the nested multiple comparisons). Known protein-protein interactions were examined for classifier members as well as with other genes using the Metacore database. In addition to examining functional enrichment, potential sub-networks (or "small networks") in the classifier were examined using known and curated protein-protein interactions from the MetaCore database™. These sub-networks were ranked based on statistical For personal use only. on November 12, 2017. by guest www.bloodjournal.org From significance and the number of known biological pathways found in the sub-network.
The p-values are based on a hypergeometric distribution in which the p-value essentially represents the probability of particular mapping arising by chance, given the numbers of genes in the set of all genes on maps/networks/processes, genes on a particular map/network/process, and genes in the experiment. This is formally defined as:
where N = total number of nodes in MetaCore database; R = number of the network's objects corresponding to the genes and proteins in your list; n = total number of nodes in each small network generated from your list; r = number of nodes with data in each small network generated from your list 15 .
Metanalysis. CEL files for the Yong et al paper were provided by the authors. The data was analyzed similarly to that of the training set (RMA normalization, one-way ANOVA).
Reported fold changes and p-values for the Zheng et al. data set 16 were downloaded from the journal website. Overlap was calculated based on the number of shared putative differentially expressed genes. Simulations in the statistical computing environment R were performed to determine the number of overlapping features (O) expected to be shared among two candidate lists of different lengths (n1, n2) both sampled from the same array (with N features). Statistical significance was determined by comparing the observed value (o) with the distribution generated from 10,000
simulations performed for a given configuration (n1, n2, N). Standard analysis tools were applied to patient characteristics. Low-level analysis of the Affymetrix data was conducted using the Robust Multi-array Average (RMA) algorithm 13 . Transcript-bytranscript ANOVA to determine differential expression between non-responders and responders was performed on the training set. Testing of the classifier was performed on the independent, blinded validation set. With regard to downstream analysis of the classifier, over-represented gene ontology and pathway annotations were identified in the classifier transcripts using categorical data analysis. Known protein-protein interactions were examined for classifier members as well as with other genes using the Metacore database™.
Results
Baseline characteristics of the training set. Overall, the process of CD34+ cell selection, RNA extraction and array hybridization was successful in 36 of 51 patients (71%), amongst them 24 non-responders and 12 responders. Nineteen samples failed at one of the quality control steps during samples processing. FISH for BCR-ABL was successful in 28 of 36 patients (78%) and revealed between a small but statistically significant difference between non-responders and responders (median of 100% vs.
98.5%, P = 0.01). Compared to responders, non-responders tended to be older (P = 0.048) and had a longer interval between diagnosis and imatinib start (P = 0.037), but there were no other significant differences ( Table 1) .
Construction of the response classifier.
To determine whether the gene expression profiles of CD34+ cells from prospective cytogenetic responders and non-responders are different, we performed unsupervised hierarchical cluster analysis. We found partial and statistically significant separation between responders and non-responders (P = 0.024) (Figure 1 Table 2 ). Fifty of these transcripts were up-regulated and twenty-five were down-regulated in non-responders vs. responders.
Validation of the response classifier in an independent test sample. For validation,
we prospectively collected CD34+ cells from 42 newly diagnosed chronic phase patients prior to starting imatinib. Twenty-three samples (55%) past all the quality control steps and were included in the analysis. Seventeen (74%) of these patients achieved CCyR within 12 months (Table 3) , in keeping with the results of the IRIS study 17 . Microarray analysis was carried out using the same protocol as for the training set. As with the training set, we first performed unsupervised cluster analysis using the 75-probe set classifier. Responders were readily separated from non-responders ( Figure 2 ). Next, we applied the prediction algorithm to the validation set. Correct predictions were made in 15/17 responders and 5/6 non-responders, for an estimated accuracy rate of 86.9% (Table 3) . (Table 5) .
Discussion
CML patients with primary cytogenetic resistance, defined as the failure to achieve . Lack of compliance with the medication may also play a role and is impossible to exclude without unannounced drug level testing. Nonetheless, the strong predictive value of MCyR at 12 months has stimulated research to identify biomarkers to predict cytogenetic response upfront. Several studies have used expression arrays on pre-therapeutic samples to identify signatures associated with cytogenetic response 12, [23] [24] [25] [26] . These studies differ in the source of the RNA (whole blood, total white cells, MNC) as well as the array and bioinformatics platforms employed. While all but one study reported the identification of a gene classifier predicting cytogenetic response, there is no overlap between the gene lists.
Without independent control groups for validation the reproducibility of these findings remains to be determined. In our own experience, applying stringent analysis criteria and an independent validation set, we found that the gene expression profiles of unselected white cells from responders and non-responders were very similar 12 . This is consistent with the observation that almost all chronic phase patients achieve a complete hematologic response, suggesting that the bulk of the (differentiated) leukemia cells are sensitive to imatinib, irrespective of the subsequent cytogenetic response that occurs over the course of months. We therefore decided to analyze CD34+ cells as a more primitive cell population.
In a first set of experiments we optimized the purification of CD34+ cells from cryopreserved MNC as well as the subsequent steps of RNA extraction, amplification and hybridization, using several stringent quality control steps. While the numbers of . Up-regulation of ANGPT1, the ligand of Tie2, in non-responders points to activated angiogenesis and is consistent with the observation that high microvessel density is an adverse prognostic feature in CML 28 . In fact, pathway analysis using MetaCore suggests that ANGPT1 may be a critical node in a network that involves protein tyrosine kinase signalling from transmembrane receptors. Last, there are three transmembrane carriers in the classifier, two of which (SCL22A4, also known as OCTN and SLC16A6) are expressed at lower and one (SCL8A3) are expressed at higher levels in non-responders. Given that low activity or expression of OCT1, a member of the same family of carriers as SCL22A4 (also known as OCTN1), predicts a lower likelihood of achieving a major cytogenetic or major molecular response [29] [30] [31] [32] , we have performed functional studies to assess whether OCTN1 may be a carrier of imatinib. However, we have not found evidence for this (Supplemental Figure 3) . The potential role of the other two carriers remains to be determined. On the other hand, expression of OCT1 was below background in our study. The reason for our failure to detect an association between OCT1 expression in CD34+ cells and response is not immediately obvious, given that we and others previously described a correlation between high OCT1 levels in mononuclear cells and subsequent MCyR 30, 31 . One possibility is that the probe set on the microarray fails to detect splice variants specific to CD34+ cells. Additionally, it has become clear that the role of drug transporters for imatinib response is complex. For example, certain MDR1 33, 34 .
A comparison with published data revealed that a subset of the genes contained in the minimal list have previously been associated with prognosis and disease stage in CML. For example, low expression of myeloperoxidase and cathepsin G, both reduced in non-responders, was previously shown to predict for a short duration of chronic phase in patients treated with conventional non-imatinib therapy 21 . Down-regulation of CEBPB and up-regulation of GAS2 and ANGPT1 have been shown in CML blast crisis compared to chronic 35, 36 ; the identical regulation pattern is seen in non-responders vs.
responders. These observations suggested that a subset of the genes associated with primary cytogenetic resistance may in fact reflect more advanced disease. We therefore performed metanalysis using two previously published data sets on CD34+ CML cells 16, 21 . We found highly significant overlap with genes differentially expressed between patients with a short and long chronic phase on conventional non-imatinib therapy 21 as well as a signature of blastic versus chronic phase . Thus, the emerging picture is that gene expression profiling allows for a more precise diagnosis of disease phase than morphological criteria. Given the correlation between disease phase and cytogenetic response [38] [39] [40] , it is perhaps not surprising that gene expression profiling is a better predictor of response than morphology, at least in the chronic phase. Conversely, it will be interesting to determine whether patients with advanced CML who achieve CCyR have expression profiles that resemble chronic phase. While it remains to be determined how precisely the genes identified in our analysis contribute to cytogenetic resistance, one may speculate that they reflect the evolution of the disease towards BCR-ABL independence 41 . Clearly, additional factors, such as drug transport proteins, are likely to play a role as well 31, 32 . Altogether, the metanalysis suggests that chronic patients destined to primary cytogenetic resistance have more advanced disease than suggested by morphological criteria.
In summary, we have identified a gene expression profile that predicts MCyR with a high degree of accuracy. To our knowledge, this is the first prospectively validated gene expression classifier of cytogenetic response to imatinib. The ability of the classifier to identify high risk patients more accurately than the Sokal score may allow targeting more intensive therapy to the patients most likely to benefit. CE -clonal cytogenetic evolution. *Two patients (1 responder and 1 non-responder) were subsequently found to fulfill the criteria for accelerated phase (platelet count <100/nL unrelated to therapy, and basophils in the blood >20%). **Patients with CE were classified as in accelerated phase in the phase 2 imatinib studies (but not in the IRIS study) and therefore treated with an initial dose of 600 mg imatinib daily ), which included two ANGPT1 signaling related pathways (both part of MetaCore Curated Map 532). The key classifier node that linked both of these pathways was ANGPT1. Red circles indicate genes up-regulated in non-responders. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
